Lucast Plus

# Lucast plus ## Overview - **Classification**: Leukotriene Receptor Antagonist (Montelukast) + Second-generation Antihistamine (Levocetirizine). - **Mechanism**: Montelukast blocks leukotriene D4, reducing inflammation. Levocetirizine selectively antagonizes peripheral H1-receptors, reducing histamine effects. ## Primary Indications 1. **Allergic Rhinitis**: Symptomatic relief of seasonal and perennial allergic rhinitis. 2. **Asthma with Allergic Rhinitis**: Management of mild-to-moderate asthma when co-existing with allergic rhinitis. 3. **Chronic Urticaria**: Symptomatic relief of chronic idiopathic urticaria. ## Adult Dosing ### Standard Dosing **Allergic Rhinitis, Asthma with Allergic Rhinitis, Chronic Urticaria** - **Dose**: **Montelukast 10 mg** / **Levocetirizine 5 mg** (fixed-dose combination) - **Frequency**: Once daily, preferably in the evening. - **Route**: Oral - **Duration**: As needed for symptom control. ### Dose Adjustments - **Renal Impairment**: * CrCl 50-79 mL/min: No adjustment needed. * CrCl 30-49 mL/min: Consider dose reduction to alternate day, or use individual components. * CrCl <30 mL/min: Contraindicated (due to levocetirizine accumulation). - **Hepatic Impairment**: No specific dose adjustment generally recommended for mild-to-moderate impairment. - **Elderly Patients**: Monitor renal function; initiate with caution due to potential for decreased renal clearance. ## Pediatric Dosing *(Note: Use of fixed-dose combinations in very young children is generally not recommended due to difficulty in precise dosing for each component. Individual agents preferred.)* ### Neonates (0-28 days) - **Dose**: Not recommended. - **Special Notes**: Safety and efficacy not established. ### Infants (1-12 months) - **Dose**: Not recommended. - **Special Notes**: Safety and efficacy not established for this combination. ### Children (1-12 years) **Allergic Rhinitis, Asthma with Allergic Rhinitis** - **Children 6-12 years**: * **Dose**: **Montelukast 5 mg** / **Levocetirizine 2.5 mg** (fixed-dose combination). * **Frequency**: Once daily, in the evening. * **Route**: Oral * **Maximum**: Do not exceed adult doses for individual components. - **Children 2-5 years**: * **Dose**: **Montelukast 4 mg** / **Levocetirizine 2.5 mg** (fixed-dose combination, if available). * **Frequency**: Once daily, in the evening. * **Route**: Oral * **Maximum**: Do not exceed. * **Special Notes**: Chewable tablets or granules may be available for Montelukast; liquid formulations for Levocetirizine. Use appropriate age-specific formulation. ### Adolescents (13-18 years) **Allergic Rhinitis, Asthma with Allergic Rhinitis, Chronic Urticaria** - **Dose**: Follow adult dosing. **Montelukast 10 mg** / **Levocetirizine 5 mg**. - **Frequency**: Once daily, in the evening. - **Route**: Oral - **Maximum**: **Montelukast 10 mg / Levocetirizine 5 mg** per day. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Montelukast, Levocetirizine, or cetirizine. - **Absolute**: Severe renal impairment (CrCl <10 mL/min for Levocetirizine). - **Absolute**: End-stage renal disease requiring dialysis. ### Common Adverse Effects - **Very Common (>10%)**: Headache (Montelukast), Somnolence/Drowsiness (Levocetirizine). - **Common (1-10%)**: Dry mouth, fatigue, dizziness, nasopharyngitis, abdominal pain, diarrhea. - **Serious but Rare**: * **Neuropsychiatric Events**: Agitation, aggression, depression, suicidal thoughts/behavior (Montelukast). * **Hepatotoxicity**: Elevated liver enzymes, cholestatic hepatitis. * **Hypersensitivity Reactions**: Anaphylaxis, angioedema. ### Key Drug Interactions - **CNS Depressants (Alcohol, Sedatives)**: Increased risk of CNS depression and impaired performance. - **Ritonavir**: May increase plasma levels of Levocetirizine, increasing risk of adverse effects. - **Phenobarbital, Rifampin**: May decrease Montelukast levels, reducing efficacy. ## Monitoring & Follow-up - **Before Treatment**: Assess renal function (especially in elderly). Evaluate baseline psychological status. - **During Treatment**: * **Clinical Efficacy**: Monitor for improvement in allergy/asthma symptoms. * **Adverse Effects**: Monitor for CNS depression, dry mouth. * **Neuropsychiatric Symptoms**: Monitor for changes in mood, behavior, or suicidality. - **Clinical Signs**: Watch for unexplained fatigue, yellowing skin/eyes (hepatic issues). ## Clinical Pearls - 💡 **Timing**: Administer in the evening for optimal effect on nocturnal symptoms and to mitigate drowsiness. - 💡 **Not for Acute Asthma**: This combination is for maintenance therapy; not for acute asthma attacks or status asthmaticus. - 💡 **Neuropsychiatric Risk**: Counsel patients/caregivers on potential neuropsychiatric symptoms (agitation, depression, suicidal thoughts) and to seek immediate medical advice if they occur. - 💡 **Driving/Operating Machinery**: Warn patients about potential drowsiness, especially when initiating therapy or consuming alcohol. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.